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Abstract
Amyloidosis is a rare multiorgan disease defined by a process of irreversible, 
extracellular accumulation of fibrillar proteins in the tissues, including the heart. 
Cardiac involvement is seen in most forms of amyloidosis, but it is frequently present 
and clinically significant in light chain (AL)-amyloidosis as well as transthyretin amy-
loidosis (ATTR). Cardiac amyloid accumulation leads to a restrictive filling pattern, 
which must be differentiated from other forms of restrictive and hypertrophic cardio-
myopathies due to consequences for the treatment. Evolving knowledge of the disease 
has led to a definite diagnosis of the cardiac amyloidosis (CA) using non-invasive and 
low-risk diagnostic features, such as scintigraphy (gamma scan) and cardiovascular 
magnetic resonance (CMR) imaging using late gadolinium enhancement (LGE) and 
T1 mapping technics. The availability and diagnostic accuracy of these technics has 
reduced the need for cardiac biopsy. In the following chapter, we will describe com-
mon types of CA, the basic concepts, and updates of non-invasive diagnostic features.
Keywords: Cardiac Amyloidosis, Diagnosis, Non-Invasive Technics,  
Imaging Modalities
1. Introduction
1.1 Common types of amyloidosis
Amyloidosis is an infiltrative disease defined by extracellular accumulation of 
fibrillar proteins in the tissues, including the heart (cardiac amyloidosis (CA)). 
Lately, about 30 different types of amyloidosis have been described, each due to a 
specific misfolded protein [1]. Some types of amyloidosis are hereditary others are 
caused by abnormal organ or plasma cells producing a precursor protein. Additional 
causes involve long-term dialysis or inflammatory diseases. The disease is classified 
as “localized amyloidosis” and “systemic amyloidosis”.
The main subtypes of amyloidosis are summarized in the following:
• Light chain amyloidosis (AL, primary amyloidosis): AL-amyloidosis 
represents the most common type of amyloidosis with a prevalence of >0.3 per 
100,000 of the general population. The incidence is estimated at 8.9–12.7 per 
million person-years [2]. The age at manifestation is usually between 60 and 
69 years. Precursor protein in AL-amyloidosis is a misfolded immunoglobulin 
light chain produced by plasma cells. Deposition of misfolded proteins can 
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occur in virtually any organ system. However, in most cases, the heart and 
kidneys are involved. Cardiac involvement is described in more than 70% of 
the cases with a mortality rate of up to 50% per year after the first episode of 
an acute heart failure [3]. The development of AL cardiomyopathy is caused by 
the AL amyloid-associated lysosomal dysfunction, oxidative stress, and induc-
tion of autophagy (direct toxicity) [4].
• Amyloid transthyretin (ATTR)-amyloidosis: ATTR-amyloidosis is a life-
threatening and progressive type of amyloidosis. Two forms of ATTR can be 
distinguished, the mutant transthyretin (ATTRm, referred to as familial or 
hereditary transthyretin amyloidosis (FTA)) and the wild-type amyloidosis 
(ATTRwt, known as well as senile systemic amyloidosis). The precursor pro-
tein is amyloid transthyretin (TTR), a transport protein, which usually carries 
thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol 
in serum and cerebrospinal fluid.
• ATTRm is an autosomal dominant condition caused by mutations in the TTR 
gene with abnormal secreted by the liver and deposited in various organs. 
The type and severity of organ involvement defines its prognosis. ATTRm is 
clinically heterogeneous and causes a broad spectrum of symptoms. Most often 
patients suffer from mixed clinical phenotype consisting of sensory and motor 
impairment and multiple organ failure [5]. Although the exact prevalence of 
ATTRm is unknown, recently published data reported a global prevalence 
as high as 38,000 persons [5]. In African Americans ATTR-CA is frequently 
associated with the mutation Val142Ile (formerly known as Val122Ile), which is 
carried by 10% of African Americans with heart failure with reduced ejection 
fraction (HFrEF) and by 1.5–3.5% of the general African American population 
[6]. In the general Caucasian population this mutation is extremely rare (< 
0.005%) [7, 8].
• ATTRwt is the most common cause of CA, particularly in the elderly. In a 
population-based autopsy study Tanskanen M, et al. showed its presence in 
25% of subjects aged >85 years [9]. Several studies presented concomitant 
ATTRwt-amyloidosis in patients with severe aortic stenosis and heart failure 
with preserved ejection fraction (HFpEF) [10]. The prevalence among patients, 
who underwent transcatheter aortic valve implantation (TAVI) was reported in 
8–16% [11]. However, the prevalence in patients with (paradoxical) low-flow, 
low-gradient aortic stenosis was reported much higher, with up to 30% [12]. 
The amyloid protein is being stored in every structure of the heart including 
myocardium, valves, and coronary arteries. The accumulation of dysfunctional 
proteins in the extracellular space of the myocardium leads to stiffening of the 
muscle and impairs the diastolic function of the heart. Heart failure occurs due 
to a restrictive filling pattern and impaired systolic function. Common arrhyth-
mias resulting from structural changes usually include atrial fibrillation, 
atrioventricular block (AV), and sudden cardiac death (SCD) due to bradyar-
rhythmia or tachyarrhythmia [13].
• Serum amyloid A amyloidosis (SAA, secondary amyloidosis): An acute-
phase protein produced in the liver represents the precursor protein of SAA. 
An inflammatory disease, such as autoimmune and autoinflammatory disease, 
chronic infections, or cancer disease may trigger its production. The most com-
monly affected organs are the kidneys, liver and spleen. Cardiac involvement 
in SAA is rarely described in the literature [14].
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• Localized amyloidosis: In localized amyloidosis the amyloidogenic protein 
is deposited at the site of production and not transported via bloodstream. 
Localized amyloidosis is usually light chain associated, but also serum amy-
loid A protein and TTR have been reported as localized disease. Localized 
immunoglobulin AL-amyloidosis is a rare disease. In a large study by the Mayo 
clinic 403 of 5551 AL patients (7%) were found for localized immunoglobulin 
AL-amyloidosis [15]. In this study, the median follow-up for survival and 
progression were 72 and 39 months. Localized amyloidosis is characterized 
by deposition of amyloid in a limited area of an anatomical region, such as 
isolated atrial amyloidosis caused by the precursor protein of atrial natriuretic 
factor (ANF) [16]. All tissues may be involved, but localized amyloidosis typi-
cally involves the laryngo-tracheobronchial tree, skin and urogenital tract.
1.2 Cardiac amyloidosis
CA is a leading cause of restrictive cardiomyopathy due to interstitial deposits of 
amyloid impairing the elasticity and contractility of the myocardium and leaving 
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Overview of the main subtypes of amyloidosis with the possibility of cardiac involvement.
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the muscle stiff. Early findings include abnormal myocardial relaxation, gradually 
advancing to restrictive filling pattern, with signs and symptoms of heart failure. 
As specified above, the most common types of CA are AL and ATTR-amyloidosis 
(Table 1). An early diagnosis is of paramount importance in order to start the ade-
quate treatment according to the disease, which determines the patient’s prognosis.
Previously, the gold standard of CA diagnosis was a histological analysis of 
endomyocardial tissue. The invasive nature of an endomyocardial biopsy (EMB) 
limits its routine application. The following immediate or late complications are 
associated with EMB: pericardial effusion with or without tamponade, arrhythmias, 
tricuspid valve damage, pneumothorax, pulmonary embolism, nerve paralysis, 
bleeding complications, creation of an arteriovenous fistula, venous thromboembo-
lism, and infections [17]. Major complications caused by EMB are described with a 
rate of 1% even when performed in large centers by experienced operators [18–20]. 
The cause of death is often perforation with tamponade.
Advances in imaging protocols have led to them being primarily used in daily 
clinical routine. The following chapter provides diagnostic steps for patients with 
CA including the most recent literature.
2. Non-invasive diagnostic techniques
2.1 Standard 12-lead electrocardiography (ECG) and Holter-ECG monitoring
The diagnostic procedure starts with a simple electrocardiogram (ECG), which 
may already provide clues for the presence of CA. Historically, CA is a condition 
associated with low voltage in the ECG, which usually is defined as a peak-to-peak 
QRS amplitude of less than 5 millimeters in the limb leads and/or less than 10 mil-
limeters in the precordial leads [21].
Rapezzi et al. analyzed ECG recordings of AL, ATTRm and ATTRwt-
amyloidosis and found significant differences among the three groups for low 
QRS voltage and left bundle-branch block [22]. Left bundle-branch block was 
frequently present in ATTRwt (40%), while in AL low QRS voltage was more 
common (25% ATTR versus 60% in AL). Boldrini et al. assessed the prevalence 
of intraventricular and atrioventricular conduction delays in a cohort of 344 AL 
patients. Intraventricular conduction delay due to myocardial amyloid deposits 
was associated with worse systolic function, higher mortality, and higher levels of 
cardiac biomarker [23]. Further 276 patients with a diagnosis of systemic amyloi-
dosis, admitted to the Beijing Union Medical College Hospital from January 2000 to 
December 2011, were evaluated by Cheng and colleagues [24]. The study reported 
atrial arrhythmia, low voltage on limb leads, AV-block, and pseudo-infarct pattern 
as the most present ECG pattern in CA than control groups. In summary, the study 
data suggests a high specificity and a positive predictive value of low voltage on limb 
leads and pseudo-infarct pattern for the diagnosis of CA. However, these features 
are only observed in some CA patients (50% AL and 30% ATTR) and often in a 
later stage of the disease [25].
The most frequent arrhythmias in CA are atrial fibrillation (45–65%), ventricu-
lar tachyarrhythmias (ventricular tachycardia 9.9% and ventricular fibrillation 
0.7%) and AV conduction delays (3.5%) [26]. The risk of SCD is increased, espe-
cially in advanced disease. The Austrian hot spot mutation His108Arg is linked to an 
increased incidence of ventricular tachycardia [27]. The proarrhythmic substrate 
for ventricular arrhythmias in CA is left ventricular fibrosis leading to micro- and 
macro-reentrant circuits [28]. Therefore, Holter-ECG monitoring is recommended 
in CA at initial presentation and follow-up.
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Although electrophysiological studies (EPS) do not serve as a diagnostic tool, 
research supports their prognostic relevance. For example, in a study by Reisinger et 
al., 92% had a prolonged His-ventricular (HV) interval (>55 ms), which was identi-
fied as an independent predictor of SCD on multivariate analysis among patients 
with AL [29]. In a recently published study by Orini et al., ventricular conduction 
and repolarization abnormalities were more pronounced in AL compared to ATTR-
amyloidosis [30].
In conclusion, in patients with AL and ATTR-amyloidosis, ECG and Holter-
monitor are important tools to diagnose AV conduction delays as well as atrial 
and ventricular arrhythmias. Implantation of a permanent pacemaker system is 
recommended in patients meeting the established criteria for device implantation 
[31]. EPS should be considered in the setting of unexplained syncope due to the fact 
of common HV prolongation in absence of AV-Block in the 12-lead ECG. Patients 
with AL-amyloidosis have a higher risk to develop arrhythmias and suffer from a 
poor prognosis. However, implantable cardioverter defibrillator (ICD) for primary 
prophylactic therapy did not show a survival benefit in AL-CA. Their use may be 
considered in patients with AL or ATTR associated CA complicated with ventricular 
arrhythmias causing hemodynamic instability, who are having a life expectancy of 
more than one year with good functional status [32–34].
2.2 Cardiac biomarker and laboratory parameter
In suspected CA further laboratory parameters are needed. Due to an underlying 
plasma cell dyscrasia in AL-amyloidosis, a monoclonal gammopathy is detected 
by electrophoresis and immunochemical measurements of specific isotypes or 
free light chains (FLC) pairs. The spike of light chains is referred as “Bence Jones 
protein”. For detection of even small amounts of FLC a serum fluorescence lifetime 
correlation spectroscopy and a serum FLC (sFLC) assay are of great additional 
value [35]. If monoclonal proteins are identified, the patient should be referred to 
a hematologist for further evaluation including a bone marrow biopsy. In case, an 
AL-amyloidosis can be ruled out, the next step should involve Technetium (Tc) 
-labeled cardiac scintigraphy (for further details see chapter 2.5).
Incorporation of sFLC differentiation into the current staging system for 
AL-amyloidosis improves risk stratification therapy optimization. Increased values 
of cardiac biomarkers such as brain natriuretic peptide (BNP), N-terminal brain 
natriuretic peptide (NT-proBNP), and Troponin (TnI, TnT) are used as screening 
parameters for cardiac involvement and clinical outcome. They might also assess the 
treatment response. In general, natriuretic peptides and Troponin levels are com-
monly elevated in CA, with a mild elevation seen in ATTR and higher levels in AL 
due to a cardiotoxic effect of light chains. The Mayo classification consists of TnT, 
NT-proBNP, and FLC-ratio (difference between light chain kappa and lambda) and 
helps estimating cardiac involvement and prognosis in AL patients [36].
2.3 Echocardiography
Echocardiography is an essential screening tool for CA and speeds up diagnosis. 
The most important finding represents the ventricular hypertrophy associated with 
amyloid self-aggregation (Figure 1). However, left ventricular (LV) wall thickening 
may also be seen in other conditions, such as long-standing arterial hypertension, 
high-grade aortic stenosis, hypertrophic cardiomyopathy (HCM) or storage dis-
eases such as Fabry’s disease. Therefore, further echocardiographic characteristics 
such as thickening of the atrial septum, valvular leaflets, as well as enlarged atria 
and pericardial effusion raise suspicion towards CA. Furthermore, assessment of 
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diastolic function is a useful evaluation tool for CA. Diastolic dysfunction usually 
appears before pathologic measurements of left or right ventricular (RV) walls and 
it is the hallmark of amyloid heart disease [37]. A restrictive filling pattern is found 
in up to one-third of the CA population. According to the European classification 
of cardiomyopathies, CA may be regarded either as restrictive or hypertrophic 
cardiomyopathy based on the severity of diastolic filling impairment [38]. Based 
on hypertrophy and diastolic function parameters Aimo et al. developed a simple 
score named AMYLoidosis Index (AMYLI), as the product of relative wall thickness 
(RWT) and E/e’ ratio, for initial screening of CA patients (AMYLI <2.22 excludes 
the diagnosis in patients undergoing a diagnostic screening for CA) [39]. However, 
this score needs further validation and is currently not in use for clinical routine.
Historically, “sparkling myocardium” is associated with CA. Granular sparkling 
is seen in approximately 25% of CA patients, which is attributed to increased 
echogenicity of the amyloid protein [40]. However, scanning with tissue harmonic 
frequencies imparts increased echogenicity of myocardium in general and granular 
sparkling may be overdiagnosed. In general, “speckled appearance” alone is not 
diagnostic of CA, since HCM, end-stage renal disease, harmonic imaging, and 
glycogen storage disease produce similar appearance [41].
Speckle tracking as an advanced echocardiography technic is a useful tool to 
differentiate CA from other causes of LV hypertrophy including other storage 
diseases. Myocardial speckle tracking-based strain imaging of the LV can help in 
the differential diagnosis and the presence of relative apical sparing may indicate 
CA. While left ventricular ejection fraction (LVEF) is preserved at early stages of 
CA, the longitudinal systolic contraction is already impaired [40]. Typically, the 
longitudinal strain at the basal and the mid ventricular segments is reduced, while 
the longitudinal apical strain of the LV is preserved (apical sparing). Preserved 
apical strain can be visualized using the strain ratio or the bull’s eye plot (Figure 2) 
[42]. The pathophysiological basis of the apical sparing is not fully understood, but 
advanced imaging has shown evidence of amyloid deposition preferably in the basal 
and mid ventricular segments. In addition, a normal value of the global longitudinal 
strain (GLS) is known as a positive predictor for survival [43].
Although concomitant RV free wall hypertrophy is suggestive of infiltra-
tive cardiomyopathy, an additional RV apical sparing pattern has been shown to 
distinguish CA from other storage diseases. Arvidsson et al. examined RV global 
and segmental strain of 42 subjects with ATTR amyloidosis. Patients with ATTR 
amyloidosis showed an apex-to-base RV strain gradient with relative apical sparing 
[44], RV involvement has been shown to occur most commonly after LV infiltration 
and has implications for prognosis [45].
Figure 1. 
Echocardiographic imaging showing a parasternal long axis view of a left ventricular hypertrophy and an 
apical 4-chamber view demonstrating mitral regurgitation.
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To distinguish CA from other storage diseases, the following echocardiographic 
features may be helpful: presence of LV thickening, enlargement of the left atrium 
with wall thickening, lower E/e′, longer transmitral early filling wave deceleration 
time, reduced longitudinal strain in all myocardial segments with presence of rela-
tive apical sparing, additional RV hypertrophy with apical sparing pattern and mild 
pericardial and pleural effusion.
In summary, echocardiography using standard and speckle tracking imaging can 
provide many features suggesting amyloid heart disease though none of them are 
absolutely specific and further diagnostic tests are needed to accurately diagnose 
CA. Nevertheless, the presence of several echocardiographic findings increases the 
likelihood of the diagnosis, especially the combination of increased wall-thickness 
of the non-dilated LV with a restrictive filling pattern, biatrial enlargement, thick-
ened valves, and pericardial effusion.
2.4 Cardiovascular magnetic resonance (CMR)
If echocardiographic findings hint at the presence of CA, cardiovascular magnetic 
resonance (CMR) is used to provide further support for the suspected diagnosis by 
evaluation of cardiac function and morphology using steady-state free precession 
(SSFP) sequences, tissue characterization via late gadolinium enhancement (LGE) 
and T1 mapping. CMR can characterize amyloid deposition in the extracellular 
tissue via LGE. In general, the phenomenon of LGE is explained by higher regional 
gadolinium concentration in the extracellular space and reduced distribution kinetics 
than in normal myocardium. In CA, the interstitium is substantially expanded by 
amyloid fiber accumulation, which is demonstrated by LGE in the myocardium with 
a dominant subendocardial distribution (Figure 3) [46, 47]. In a study by Pennell et 
al., a diffuse subendocardial LGE was observed in 69% [48]. Next to subendocardial 
different, other distribution patterns, ranging from the global transmural LGE to 
patchy focal LGE, have been described. The differences in the LGE pattern, especially 
the “patchy distribution” was explained by incorrect TI settings [49].
Suboptimal “myocardial nulling” is characteristic of CA. It describes the impos-
sibility of adjustment of inversion time to discriminate the blood pool from the 
myocardium. An inversion recovery pulse sequence is used to null the myocardial 
signal during delayed-enhanced imaging. Usually, the blood pool reaches the null 
point before normal myocardium. However, this relationship is reversed in CA. 
Phase-sensitive inversion recovery (PSIR) reconstruction is emerging as the most 
accurate method to overcome this problem and assess LGE in CA. This technique 
Figure 2. 
Automated strain imaging using speckle-tracking algorithm.
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eliminated the difficulties of accurate TI selection, because tissue with the least 
gadolinium always appears nulled [50].
Krombach et al. described in 2007 another technic for the evaluation of CA 
using CMR [51]. The authors presented a measurement of myocardial T1 mapping 
values without application of LGE in identifying interstitial amyloid infiltration. 
Using this parameter, a sensitivity of 80% and a specificity of 94% was achieved in 
the study to diagnose CA. Determination of native and postcontrast (after applica-
tion of the contrast agent) T1 mapping, allows for calculation of the extracellular 
volume (ECV), which correlates well with histological findings based on cardiac 
biopsies [52]. Meanwhile, several studies have demonstrated an increase in native 
T1 relaxation time as well as ECV of the myocardium in CA [53]. However, the diag-
nostic significance of ECV is limited due to overlap with other myocardial diseases 
associated with LV hypertrophy. Therefore, thresholds for native T1 relaxation time 
and ECV have not been established yet [54].
Due to the above-described comprehensive technical features, CMR represents 
an alternative to biopsy and has become an established part of the standard clinical 
pathway for CA diagnosis. In addition, it may provide prognostic information for 
patients with a confirmed diagnosis.
2.5 Cardiac scintigraphy
Tc-labeled cardiac scintigraphy provides incremental value to echocardiography 
and CMR, because of the ability to distinguish ATTR CA from other forms of LV 
hypertrophy [55]. Radionuclides have affinity towards myocardial amyloid depos-
its, especially towards myocardial ATTR. The binding of the radiotracer towards 
myocardial ATTR is supposed to be due to microcalcifications [56]. Three different 
technetium-labeled radiotracers are used for the diagnosis of ATTR-CA: 99mTc-PYP 
(99mTc-labeled pyrophosphate), 99mTc-DPD (99mTc-labeled 3,3- diphosphono-
1,2-propanodicarboxylic acid), and 99mTc-HMDP (99mTc-labeled hydroxymethyl 
diphosphonate). Grading systems for the degree of uptake in the myocardium on 
planar imaging are quantitative and qualitative. Qualitative scores are based on the 
heart to contralateral lung uptake (H/CL) ratio with 99mTc-PYP or the heart to whole 
body ratio with 99mTc-DPD and 99mTc-HDMP (Figure 4) [57].
Gillmore et al. assessed the diagnostic accuracy of all three above-mentioned 
tracers in 1,217 patients with suspected CA. Any myocardial radiotracer uptake 
was >99% sensitive and 86% specific for detecting ATTR-CA, with the majority of 
false-positive results from patients with AL-amyloidosis. A higher amount of myo-
cardial radiotracer uptake (grade 2 or 3) and the absence of monoclonal proteins 
in serum or urine had nearly 100% specificity and 100% positive predictive value 
for ATTR-CA [55]. Imaging differentiation between AL and ATTR-amyloidosis 
Figure 3. 
Cardiovascular magnetic resonance imaging of myocardial late gadolinium enhancement with pronounced 
septal and basal distribution.
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is based on the 99mTc-PYP H/CL uptake ratio; a ratio of <1.5 favors AL, whereas 
a ratio of ≥1.5 favors ATTR [58]. Semi-quantitative evaluation using 99mTc-PYP 
planar imaging, a H/CL ratio of >1.5 at 1 h accurately distinguished ATTR from 
AL-CA with 97% sensitivity and 100% specificity and a whole-body retention of 
99mTc-DPD at 3 h is highly sensitive and specific for ATTR-CA [59].
In conclusion, Tc-labeled cardiac scintigraphy can reliably diagnose ATTR-
amyloidosis in the absence of tissue biopsy, especially in cases of high myocardial 
radiotracer uptake and after laboratory exclusion of AL-amyloidosis.
3. Conclusion
Cardiac involvement in amyloidosis has a high mortality rate. For instance, 
patients with AL-amyloidosis have a 50% survival rate per year after the first 
episode of acute heart failure. Rapid diagnosis and initiation of chemotherapy 
are crucial in these patients. Besides, ATTR-amyloidosis may benefit from novel 
therapeutic options to improve symptoms and survival. The following features 
should raise the suspicion of CA: patients above 60 years of age with a low-flow 
low-gradient aortic stenosis, unexplained LV hypertrophy or peripheral sen-
sory neuropathy, and patients with monoclonal gammopathy or elevated FLC 
levels. Non-invasive imaging technics are valuable in the assessment of CA and 
should be used widely. Cardiac imaging findings in echocardiography, CMR, or 
Tc-labeled bone or cardiac scintigraphy, are specific enough to diagnose CA in 
the setting of a positive non-cardiac biopsy (Figure 5). EMB with histological 
analysis of myocardial tissue is not essential anymore.
Figure 4. 
99mTc-HMDP bone scintigraphy for diagnosis of cardiac amyloidosis.
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Abbreviations
AL Light chain amyloidosis
AMYLI AMYLoidosis Index
ANF Atrial natriuretic factor
ATTR Amyloid transthyretin amyloidosis
ATTRm Mutant transthyretin amyloidosis
ATTRwt Transthyretin wild-type amyloidosis
AV atrioventricular
BNP Brain natriuretic peptide
Figure 5. 
Typical imaging features to diagnose cardiac amyloidosis.
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